PARP1 and cancer: Several PARP inhibitors, including olaparib, niraparib, rucaparib, and talazoparib, have been approved for clinical cancer treatment.[46] Meanwhile, as PARP1 overactivation triggers parthanatos in lethal oxidative stress, PARP inhibitors may be cytoprotective.